← Back to Search

Demeclocycline for Brain Tumor

Phase 1
Waitlist Available
Led By William T Curry, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

This research study is studying a drug called Demeclocycline that may help brain surgeons see tumors with a microscope during surgery.

Eligible Conditions
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Detectable fluorescence in brain tumors by confocal microscopy after oral dosing of demeclocycline (Y/N).
Secondary outcome measures
Sensitivity And Specificity Of Demeclocycline-Enhanced Multimodal Confocal Microscopy of Excised Glioma Specimens

Side effects data

From 2014 Phase 4 trial • 69 Patients • NCT01753856
11%
Constipation
11%
Post procedural discomfort
11%
Contusion
6%
Nasopharyngitis
6%
Rash
3%
Pain in extremity
3%
Appendicitis
3%
Deep vein thrombosis
3%
Diarrhoea
3%
Hypokalaemia
3%
Arthralgia
3%
Tremor
3%
Pruritus
3%
Skin induration
3%
Bronchitis
3%
Fatigue
3%
Cough
3%
Groin pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Denosumab
Teriparatide

Trial Design

1Treatment groups
Experimental Treatment
Group I: DemeclocyclineExperimental Treatment1 Intervention
All subjects will take Demeclocycline 300 mg po bid. Patients will be advised to take demeclocycline on an empty stomach, at least 1-2 hours before meals, and they will be warned that it can reduce the efficacy of oral contraceptives. The investigators will begin by treating subjects with 2 days of demeclocycline. The investigators will increase the numbers of days that subjects are exposed to demeclocycline in increments of 1 day until at least 80% of patients at a given dose have detectably fluorescent tumors, or participants reach 5 days of drug, whichever comes first.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Demeclocycline
FDA approved

Find a Location

Who is running the clinical trial?

Massachusetts General HospitalLead Sponsor
2,936 Previous Clinical Trials
13,198,681 Total Patients Enrolled
William T Curry, MDPrincipal InvestigatorMassachusetts General Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
The Lancet OncologyJournal
Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-year Analysis of the EORTC-NCIC Trial
Stupp, Roger, Monika E Hegi, Warren P Mason, Martin J van den Bent, Martin JB Taphoorn, Robert C Janzer, Samuel K Ludwin, et al.. 2009. “Effects of Radiotherapy with Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-year Analysis of the EORTC-NCIC Trial”. The Lancet Oncology. Elsevier BV. doi:10.1016/s1470-2045(09)70025-7.
clinicaltrials.govStudy
Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors
William T. Curry, MD 2016. "Demeclocycline Fluorescence for Intraoperative Delineation Brain Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02740933.
All > Brain Tumor
~4 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top